DE602005008013D1 - Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie - Google Patents

Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie

Info

Publication number
DE602005008013D1
DE602005008013D1 DE602005008013T DE602005008013T DE602005008013D1 DE 602005008013 D1 DE602005008013 D1 DE 602005008013D1 DE 602005008013 T DE602005008013 T DE 602005008013T DE 602005008013 T DE602005008013 T DE 602005008013T DE 602005008013 D1 DE602005008013 D1 DE 602005008013D1
Authority
DE
Germany
Prior art keywords
diabetic nephropathy
microal
buminuria
ctgf
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005008013T
Other languages
English (en)
Inventor
Allan Flyvbjerg
Guangjie Guo
David Y Liu
Thomas B Neff
Noelynn A Oliver
William R Usinger
Qingjian Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrogen Inc
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of DE602005008013D1 publication Critical patent/DE602005008013D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
DE602005008013T 2004-02-11 2005-02-11 Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie Active DE602005008013D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54412104P 2004-02-11 2004-02-11
US56101804P 2004-04-08 2004-04-08
US57840104P 2004-06-09 2004-06-09
US62080204P 2004-10-20 2004-10-20
PCT/US2005/004367 WO2005077413A1 (en) 2004-02-11 2005-02-11 Ctgf as target for the therapy of diabetic nephropathy

Publications (1)

Publication Number Publication Date
DE602005008013D1 true DE602005008013D1 (de) 2008-08-21

Family

ID=34865408

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005008013T Active DE602005008013D1 (de) 2004-02-11 2005-02-11 Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie

Country Status (15)

Country Link
US (2) US20050214294A1 (de)
EP (2) EP1715890B1 (de)
CN (1) CN101884789A (de)
AT (1) ATE400297T1 (de)
AU (1) AU2005212371B2 (de)
CA (1) CA2555789A1 (de)
DE (1) DE602005008013D1 (de)
DK (1) DK1715890T3 (de)
ES (1) ES2311973T3 (de)
HK (1) HK1095762A1 (de)
IL (1) IL177437A (de)
NZ (1) NZ549784A (de)
PL (1) PL1715890T3 (de)
PT (1) PT1715890E (de)
WO (1) WO2005077413A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1112088B1 (de) * 1998-09-08 2010-10-27 Henry Ford Health System Verfahren zum Nachweis von Bindegewebswachstumsfaktor zur Diagnose von Nierkrankheiten
JP2008540456A (ja) 2005-05-05 2008-11-20 ファイブローゲン、インコーポレーテッド 血管疾患の治療
ES2352801T3 (es) * 2005-12-22 2011-02-23 Kiacta Sàrl Tratamiento de nefropatía diabética.
CA2673022A1 (en) * 2006-12-22 2008-07-03 Bellus Health (International) Limited Methods, compounds, and compositions for treating metabolic disorders and diabetes
EP2190433A2 (de) * 2007-08-22 2010-06-02 Gilead Colorado, Inc. Therapie für diabeteskomplikationen
MX2011002143A (es) 2008-08-25 2011-07-20 Excaliard Pharmaceuticals Inc Oligonucleotidos antisentido dirigidos contra el factor de crecimiento del tejido conectivo y usos de los mismos.
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
HUE044178T4 (hu) 2011-02-02 2019-10-28 Excaliard Pharmaceuticals Inc Kötõszöveti növekedési faktort (CTGF) célzó antiszensz vegyületek keloidok vagy hipertrófiás hegek kezelési eljárásban történõ alkalmazásra
EP3074038B1 (de) 2013-11-28 2019-01-02 CSL Limited Verfahren zur behandlung der diabetischen nephropathie
AU2018313853A1 (en) 2017-08-08 2020-01-02 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
CN109453191A (zh) * 2018-12-06 2019-03-12 郑州大学第附属医院 GSK-3β抑制剂及在糖尿病肾病干预新靶点的应用
WO2020244540A1 (zh) * 2019-06-04 2020-12-10 江苏恒瑞医药股份有限公司 抗结缔组织生长因子抗体及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5876730A (en) 1997-08-07 1999-03-02 Childrens Hospital Research Foundation Heparin-binding growth factor (HBGF) polypeptides
EP1043335A4 (de) * 1997-12-25 2005-08-31 Japan Tobacco Inc Monoklonaler antikörper gegen den bindegewebewachstumsfaktor sowie dessen medizinische verwendungen
WO2000002450A1 (en) 1998-07-08 2000-01-20 Fibrogen, Inc. Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
EP1112088B1 (de) 1998-09-08 2010-10-27 Henry Ford Health System Verfahren zum Nachweis von Bindegewebswachstumsfaktor zur Diagnose von Nierkrankheiten
EP1127131A4 (de) 1998-11-06 2005-04-27 Fibrogen Inc Wachstumsfaktor des bindegewebes (ctgf) and verwendungsverfahren
US6348329B1 (en) * 1998-11-06 2002-02-19 Fibrogen, Inc. Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
EP1140964B1 (de) * 1998-12-14 2008-04-09 University Of Miami Fragment des "connective tissue growth factor" (ctgf)
US6706491B1 (en) 1999-04-09 2004-03-16 The Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of genes regulated by p21
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
EP1463531B1 (de) * 2001-12-11 2011-09-28 Fibrogen, Inc. Verfahren zur hemmung okularer vorgänge
CN1650001A (zh) 2002-04-30 2005-08-03 爱尔康公司 作为降低眼内压和治疗青光眼性视网膜病变 /眼神经病的独特手段的调控、抑制或调节结缔组织生长因子( ctgf)的活性和／或表达的药物
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
WO2005038013A1 (en) 2003-10-07 2005-04-28 Isis Pharmaceuticals, Inc. Artisense oligonucleotides optimized for kidney targeting

Also Published As

Publication number Publication date
PT1715890E (pt) 2008-10-17
PL1715890T3 (pl) 2009-01-30
EP1715890B1 (de) 2008-07-09
HK1095762A1 (en) 2007-05-18
DK1715890T3 (da) 2008-11-17
AU2005212371A1 (en) 2005-08-25
IL177437A (en) 2013-06-27
US20050214294A1 (en) 2005-09-29
CN101884789A (zh) 2010-11-17
ES2311973T3 (es) 2009-02-16
IL177437A0 (en) 2006-12-10
NZ549784A (en) 2008-06-30
AU2005212371B2 (en) 2010-05-13
EP1977762A1 (de) 2008-10-08
EP1715890A1 (de) 2006-11-02
CA2555789A1 (en) 2005-08-25
WO2005077413A1 (en) 2005-08-25
US20100291098A1 (en) 2010-11-18
ATE400297T1 (de) 2008-07-15
US8314059B2 (en) 2012-11-20

Similar Documents

Publication Publication Date Title
DE602005008013D1 (de) Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
ATE521608T1 (de) Glucokinaseaktivatoren
DE602005017241D1 (de) Behandlung von Gewichtsverlust bei Patienten mit entzündlichen Darmerkrankungen mittels S. boulardii
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
CY1117030T1 (el) Τροποποιηση της εκφρασης απολιποπρωτεϊνης c-iii
ATE432693T1 (de) Kombinationstherapie zur behandlung von diabetes und dadurch bedingten leiden sowie zur behandlung von mittels erhöhung des glp-1-spiegels im blut verbesserten leiden
ATE427759T1 (de) Behandlung von fettsucht und verbundenen erkrankungen
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
DK2305255T3 (da) Arylurinstofforbindelser i kombination med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
EP2006298A3 (de) Jugendliches Hämochromatose-Gen (HFE2A), Expressionsprodukte und Verwendungen davon
NO20045056L (no) Fremgangsmater for behandling av hepatitt
ATE462702T1 (de) Für die behandlung von entzündlichen krankheiten nützliche beta-carboline
DE602006002135D1 (de) Verwendung von Naloxon zur Behandlung von Essstörungen
DE602005020178D1 (de) 5,6,7-trihydroxyheptansäure und analoge zur behandlung von augenkrankheiten und mit hyperproliferativen und angiogenen reaktionen verbundenen krankheiten
ATE397924T1 (de) Satraplatin zur behandlung von resistenten oder refrkatären tumoren
DE602005019770D1 (de) Medizinische zusammensetzung zur behandlung von krebs oder diabetes
DE602008004556D1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
GB2445882A (en) Prophylactic and therapeutic agents and uses therefor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition